Postpartum Low-Dose Esketamine Aids Moms With Prenatal Depression
By Elana Gotkine HealthDay Reporter
MONDAY, April 15, 2024 -- A single low dose of esketamine after childbirth reduces depressive episodes at 42 days postpartum among mothers with prenatal depression, according to a study published online April 10 in The BMJ.
Shuo Wang, M.D., from Peking University First Hospital in Beijing, and colleagues conducted a randomized, double-blind trial with two parallel arms involving 364 mothers aged 18 years and older from five tertiary care hospitals in China with at least mild prenatal depression. Participants were randomly assigned to receive 0.2 mg/kg esketamine or placebo infused intravenously over 40 minutes after childbirth (180 and 181 women, respectively).
The researchers found that a major depressive episode was observed in 6.7 and 25.4 percent of mothers in the esketamine and placebo groups, respectively, at 42 days postpartum (relative risk, 0.26). The esketamine group had lower scores on the Edinburgh Postnatal Depression Scale at seven days (median difference, −3) and 42 days (median difference, −3). The esketamine group also had lower Hamilton Depression Rating Scale scores at 42 days postpartum (median difference, −4). The esketamine group had a higher incidence of neuropsychiatric adverse events (45.1 versus 22.0 percent); however, the symptoms lasted less than one day and did not require drug treatment.
"Low-dose esketamine should be considered in mothers with symptoms of prenatal depression," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Moving Neighborhoods in Childhood May Increase Risk for Depression in Adulthood
FRIDAY, July 19, 2024 -- Moving during childhood may increase the risk for later depression, according to a study published online July 17 in JAMA Psychiatry. Clive E...
Women More Likely to Experience Anxiety, Depression After Out-of-Hospital Cardiac Arrest
THURSDAY, July 18, 2024 -- Out-of-hospital cardiac arrest (OHCA) survivors could experience changes in employment and income, and women may have an increase in dispensing of...
Extended-Release Oral Ketamine Effective for Treatment-Resistant Depression
WEDNESDAY, July 17, 2024 -- For patients with treatment-resistant depression, racemic ketamine, given as an extended-release tablet (R-107), administered orally, is effective...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.